DP-VPA D-Pharm

Current Opinion in Investigational Drugs

Volumn 3, Issue 6, 2002, Pages 921-923

  Labiner, David M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHOLIPASE A2; PHOSPHOLIPID; PLACEBO; PRODRUG; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ABSENCE; ADD ON THERAPY; ANTICONVULSANT ACTIVITY; BENIGN CHILDHOOD EPILEPSY; BIOTECHNOLOGY; BIPOLAR DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CLONIC SEIZURE; COMPLEX PARTIAL SEIZURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME ACTIVITY; EPILEPSY; EPILEPTIC STATE; GASTROINTESTINAL SYMPTOM; HUMAN; HYDROPHOBICITY; MIGRAINE; NEUROLOGIC DISEASE; NONHUMAN; PATENT; REVIEW; SEIZURE; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIPOLAR DISORDER; CLINICAL TRIALS, PHASE II; DRUG EVALUATION, PRECLINICAL; EPILEPSY; HUMANS; MIGRAINE DISORDERS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; VALPROIC ACID;

EID: 0036628434     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. 182806 D-Pharm Ltd company profile. D-Pharm Ltd Company Brochure 1995 August
2. 242649 D-Pharm raises funds for epilepsy drug. SCRIP 1997 22238
3. 271403 Society for Neuroscience, 27th Annual Meeting (Part IV), New Orleans, USA. Bristow D IDDB Meeting Report 1997 October 25-30
4. 306173 DP-VPA, an activity-dependent prodrug of valproate, displays enhanced protection in genetically epilepsy prone mice. Friedman JE, Armstrong H, White HS, Wolf HH, Kozak A Abstr Soc Neurosci 1998 24 (Pt 2) Abs 498.4
5. 308142 Drug development pipeline: SPD-421 and DP-VPA. D-Pharm Ltd Company Communication 1998 December 04 Dr J Friedman stated that DP-VPA had completed phase I trials.
6. 339020 D-Pharm successfully completes phase-I anti-epileptic drug studies. D-Pharm Ltd Press Release 1999 September
7. 342433 European Association for Clinical Pharmacology and Therapeutics - Third Congress (Part II), Jerusalem, Israel. Hookes J IDDB Meeting Report 1999 October 3-7
8. 342913 Absorption and metabolism studies of an anti-epileptic drug, DP-VPA. Kamburg R, Margalit I, Friedman JE, Angel I, Kozak A Joint Meet EACPT3 JC4 1999 October 3-8
9. 345007 Society for Neuroscience 29th Annual Meeting (Part V), Miami, Beach, FL, USA. Kibble A, Nicholls R IDDB Meeting Report 1999 October 23-28
10. 346500 DP-VPA, a demand-regulated prodrug of valproate, in the seizure-prone Frings mouse. Friedman JE, White S, Barton M, Wolf HH, Kozak A Abstr Soc Neurosci 1999 25 (Pt 2) Abs 744.1
11. 347590 Summary of the Society for Neuroscience 29th Annual Meeting, Miami Beach, FL, USA. Kibble A, Nicholls R IDDB Meeting Report 1999 October 23-28
12. 359581 D-Pharm and Shire announce global agreement to develop DP-VPA for the treatment of epilepsy. Shire Pharmaceuticals Press Release 2000 March 14 DP-VPA consists of a valproic acid moiety chemically linked to the sn-2 position of a phospholipid carrier. This concept may be included within D-Pharm's WO-09422483, a US equivalent of which was issued in November 1999 as US-05985854.
13. 365103 Pharmabulletin. Lehman Brothers Inc 2000 April 17
14. 373232 R&D projects. Shire Pharmaceuticals Company World Wide Website 2000 June 26 http://www.shire.com
15. 373379 New Anti-epileptic Drugs - Fifth Eilat Conference Eilat, Israel. IDDB Meeting Report 2000 June 25-29.
16. 385507 D-Pharm receives technology patent - Superior activation of prodrugs in afflicted tissues offers new development and business opportunities for D-Pharm. D-Pharm Ltd Press Release 2000 October 12
17. 385862 D-Pharm's DP-B99 heads towards phase II studies; This innovative drug is expected to improve the clinical outcome in stroke, brain injury and open-heart surgery patients. D-Pharm Ltd Press Release 2000 October 16
18. 385958 D-Pharm and Shire announce global agreement to develop DP-VPA for the treatment of epilepsy. D-Pharm Ltd Press Release 2000 March 14
19. 424550 DP-VPA, a novel prodrug of valproic acid, has enhanced protective effects in genetically epilepsy-prone mice. Kozak A, Dolina S, Kamburg R, Friedman JE Abstr Soc Neurosci 1997 23 (1-2) 2163
20. 424552 DP-VPA, a novel antiepileptic prodrug of VPA, has enhanced protective effects on genetically epilepsy-prone mice. Friedman JE, Kozak A Epilepsia 1997 38 (Suppl 8) 38-39
21. 425660 D-Pharm announces the initiation of phase II clinical trials for SPD 421 by its partner Shire Pharmaceuticals. D-Pharm Ltd Press Release 2001 October 15
22. 429470 Research and development projects. Shire Pharmaceuticals Company World Wide Web Site http://www.biochempharma.com
23. 434768 Healthcare - Global Pharmaceuticals and Technology. Industry Overview: Pharma Pipelines (2002 edition). Lehman Brothers Inc 2001 December 11
24. 441819 Shire Pharmaceuticals; Fourth quarter and full year results. Shire Pharmaceuticals Company Presentation 2002 February 28
25. 449087 Equity research UK/Pharmaceuticals - Shire Pharmaceuticals. Campbell A, Crawley D, Smith J, Smith J, Swanson A, Tudor J, Vincente P Schroder Salomon Smith Barney UK/Europe 2002 March 14